CFDA approved the listing of generic drugs such as anti AIDS drug efaviron tablets

Recently, the State Food and Drug Administration approved the listing of domestic generic drugs of gefitinib, eferene and tenofovir fumarate dipivoxil Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), inhibits tumor growth, metastasis and angiogenesis by selectively blocking the signal transduction pathway of EGFR Efeverene is a selective non nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) It has a high oral bioavailability and a long half-life It is clinically used in the treatment of HIV-1 infection in adults, adolescents and children over 3 years old Its clinical effect is relatively accurate Tenofovir fumarate dipivoxil is a nucleotide reverse transcriptase inhibitor (NtRTI), which can be used in combination with other antiretroviral drugs to treat HIV 1 infection The above products are the first-line commonly used therapeutic drugs in the relevant treatment fields Jifeitini tablets produced by Qilu Pharmaceutical (Hainan) Co., Ltd., yifeiwelun tablets produced by Shanghai desino biomedical Co., Ltd and tenofovir fumarate dipivoxil tablets produced by Chengdu Beite Pharmaceutical Co., Ltd approved by the General Administration of the people's Republic of China are all the first successful imitations in China, basically consistent with the quality and efficacy of the original drugs At the same time, the General Administration approved the listing of corresponding domestic APIs, and realized the localization from APIs to preparations Since the beginning of 2016, the General Administration has given priority to the review and approval of innovative drugs for the prevention and treatment of AIDS, malignant tumors, major infectious diseases, rare diseases and other diseases, as well as drugs in urgent clinical need By the end of December 2016, 12 batches of drug priority review and approval catalogue had been published, involving 191 registration applications In the follow-up, the General Administration will continue to increase its support for the R & D and application of drugs with obvious clinical value, treatment of AIDS and other major diseases, encourage drug innovation, improve drug quality, and improve the safety and accessibility of drug use for the majority of patients.